Clinical trials for Blastic plasmacytoid dendritic cell neoplasm
6 recruiting or active trials synced from ClinicalTrials.gov.
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data- RECRUITINGPHASE1, PHASE2NCT07523555Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic MalignanciesBeijing Biotech
- RECRUITINGPHASE1, PHASE2NCT06006403Safety and Efficacy of CD123-targeted CAR-NK for Relapsed/Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell NeoplasmChongqing Precision Biotech Co., Ltd · PI: Jia Wei, M.D
- RECRUITINGNCT05430971Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International RegistryImmune Oncology Research Institute · PI: Astghik Voskanyan, MD
- RECRUITINGPhase 2NCT04216524Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell NeoplasmM.D. Anderson Cancer Center · PI: Naveen Pemmaraju
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT03386513Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCNAbbVie · PI: ABBVIE INC.
- RECRUITINGPhase 1NCT03113643SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Dana-Farber Cancer Institute · PI: Andrew Lane, MD, PhD